Cargando…

Lenvatinib treatment for thyroid cancer in COVID era: safety in a patient with lung metastases and SARS-CoV-2 infection

During the coronavirus disease 2019 (COVID-19) pandemic, clinicians are required to manage patient care for pre-existing conditions. Currently, there are no clear indications regarding the management of lenvatinib-treated patients for radioiodine-refractory thyroid cancer and severe acute respirator...

Descripción completa

Detalles Bibliográficos
Autores principales:	Locantore, Pietro, Del Gatto, Valeria, Corsello, Andrea, Pontecorvi, Alfredo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517101/ https://www.ncbi.nlm.nih.gov/pubmed/34183494 http://dx.doi.org/10.1097/CAD.0000000000001097

Ejemplares similares

The Interplay between Immune System and Microbiota in Osteoporosis
por: Locantore, Pietro, et al.
Publicado: (2020)

Medical Approaches in Adrenocortical Carcinoma
por: Paragliola, Rosa Maria, et al.
Publicado: (2020)

Pediatric Cushing's Disease and Pituitary Incidentaloma: Is This a Real Challenge?
por: Paragliola, Rosa Maria, et al.
Publicado: (2014)

Molecular Characterization of Thyroid Follicular Lesions in the Era of “Next-Generation” Techniques
por: Rossi, Esther Diana, et al.
Publicado: (2022)

Switching From Immediate-Release to Fractionated Dual-Release Hydrocortisone May Improve Metabolic Control and QoL in Selected Primary Adrenal Insufficiency Patients
por: Delle Cese, Francesca, et al.
Publicado: (2021)

Role of Mitotane in Adrenocortical Carcinoma – Review and State of the art
por: Paragliola, Rosa Maria, et al.
Publicado: (2018)

Cortisol circadian rhythm and jet-lag syndrome: evaluation of salivary cortisol rhythm in a group of eastward travelers
por: Paragliola, Rosa Maria, et al.
Publicado: (2021)

Factors Predicting Time to TSH Normalization and Persistence of TSH Suppression After Total Thyroidectomy for Graves' Disease
por: Paragliola, Rosa Maria, et al.
Publicado: (2019)

Cushing’s Syndrome Effects on the Thyroid
por: Paragliola, Rosa Maria, et al.
Publicado: (2021)

Clinical Concepts on Thyroid Emergencies
por: Papi, Giampaolo, et al.
Publicado: (2014)

Pregnancy and Prenatal Management of Congenital Adrenal Hyperplasia
por: Cera, Gianluca, et al.
Publicado: (2022)

Parathyroid Carcinoma All-In-One, a Rare Life-Threatening Case With Multiple Systemic Manifestations: Case Report and Review of the Literature
por: Zelano, Lorenzo, et al.
Publicado: (2022)

Lenvatinib for Anaplastic Thyroid Cancer
por: Tahara, Makoto, et al.
Publicado: (2017)

Efficacy and Safety of Lenvatinib in Anaplastic Thyroid Carcinoma: A Meta-Analysis
por: Huang, Dongmei, et al.
Publicado: (2022)

The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma
por: Lee, Matthew Man Pok, et al.
Publicado: (2023)

Rationale Efficacy and Safety Evidence of Lenvatinib and Pembrolizumab Association in Anaplastic Thyroid Carcinoma
por: Boudin, Laurys, et al.
Publicado: (2022)

Updates from Our Institutional Experience with Thyroid Nodules Diagnosed as Metastases
por: Rossi, Esther Diana, et al.
Publicado: (2023)

Bone Metabolism Effects of Medical Therapy in Advanced Renal Cell Carcinoma
por: Paragliola, Rosa Maria, et al.
Publicado: (2023)

Treating Hypopituitarism in the Over 65s: Review of Clinical Studies
por: Paragliola, Rosa Maria, et al.
Publicado: (2023)

Genetic Basis of ACTH-Secreting Adenomas
por: Locantore, Pietro, et al.
Publicado: (2022)

Use of multikinase inhibitors/lenvatinib concomitant with antiresorptive therapy for bone metastases from radioiodine‐resistant differentiated thyroid cancer
por: Navarro‐Gonzalez, Elena
Publicado: (2022)

A Case of Pneumothorax after Treatment with Lenvatinib for Anaplastic Thyroid Cancer with Lung Metastasis
por: Yamazaki, Haruhiko, et al.
Publicado: (2018)

Parathyroid Gland Involvement by Thyroid Cancer: Results from a Large Series of Thyroidectomies Performed in Two Italian University Hospitals and Review of the Literature
por: Papi, Giampaolo, et al.
Publicado: (2014)

Prolonged duration of response in lenvatinib responders with thyroid cancer
por: Gianoukakis, Andrew G, et al.
Publicado: (2018)

Optimal use of lenvatinib in the treatment of advanced thyroid cancer
por: Takahashi, Shunji, et al.
Publicado: (2017)

Efficacy of lenvatinib in a patient with anaplastic thyroid cancer
por: Oishi, Kazuyuki, et al.
Publicado: (2017)

Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma
por: Roque, João, et al.
Publicado: (2023)

Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program
por: Balmelli, Catharina, et al.
Publicado: (2018)

Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma
por: Takinami, Masaki, et al.
Publicado: (2020)

Editorial: The Unusual Presentation of Thyroid Disorders
por: Papi, Giampaolo, et al.
Publicado: (2019)

Lenvatinib and selpercatinib successfully treated RET fusion gene-positive papillary thyroid carcinoma cardiac metastases: a case report
por: Toda, Soji, et al.
Publicado: (2023)

Anaplastic thyroid carcinoma diagnosed after treatment of lenvatinib for papillary thyroid carcinoma
por: Yamazaki, Haruhiko, et al.
Publicado: (2019)

Exposure–response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer
por: Hayato, Seiichi, et al.
Publicado: (2018)

Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy
por: Sho, Takuya, et al.
Publicado: (2021)

Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
por: Stjepanovic, Neda, et al.
Publicado: (2014)

Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives
por: Costa, Ricardo, et al.
Publicado: (2016)

Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma
por: Hirooka, Masashi, et al.
Publicado: (2018)

Lenvatinib Promotes the Antitumor Effect of Doxorubicin in Anaplastic Thyroid Cancer
por: Su, Xi, et al.
Publicado: (2020)

Rapid disease progression after discontinuation of lenvatinib in thyroid cancer
por: Yamazaki, Haruhiko, et al.
Publicado: (2020)

Invasive procedures in patients undergoing treatment with lenvatinib for thyroid cancer
por: Toda, Soji, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d2dg2u02av5tso1cvgt5bla9ko